Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers

Autor:	Tim Svenstrup Poulsen, Helle Charlotte Knudsen, Anne Ortved Gang, Tobias Wirenfeldt Klausen, Estrid Høgdall, Peter Brown, Peter Nørgaard, Michael Pedersen, Mette Ølgod Pedersen, Signe Ledou Nielsen
Rok vydání:	2017
Předmět:	Male Oncology European People Pathology B Cells Protein Expression Biochemistry Hematologic Cancers and Related Disorders 0302 clinical medicine Animal Cells Antineoplastic Combined Chemotherapy Protocols Ethnicities Vincristine/administration & dosage lcsh:Science Etoposide Lymphoma Large B-Cell Diffuse/diagnosis education.field_of_study Fluorescent in Situ Hybridization Prognosis BCL6 Immunohistochemistry Vincristine 030220 oncology & carcinogenesis Cellular Types Proto-Oncogene Proteins c-myc/genetics medicine.medical_specialty Immune Cells Immunology Molecular Probe Techniques Proto-Oncogene Proteins c-myc 03 medical and health sciences Humans Progression-free survival Molecular Biology Techniques Antibody-Producing Cells education Molecular Biology Cyclophosphamide Danish People Retrospective Studies Pharmacology Molecular Biology Assays and Analysis Techniques Blood Cells lcsh:R Biology and Life Sciences medicine.disease Lymphoma Population Groupings lcsh:Q Cytogenetic Techniques Diffuse large B-cell lymphoma Biomarkers lcsh:Medicine Kaplan-Meier Estimate Cyclophosphamide/administration & dosage White Blood Cells Antibodies Monoclonal Murine-Derived Prednisone/administration & dosage Risk Factors immune system diseases hemic and lymphatic diseases Medicine and Health Sciences In Situ Hybridization Fluorescence Antibodies Monoclonal Murine-Derived/administration & dosage Multidisciplinary Drugs Proto-Oncogene Proteins c-bcl-6/genetics Hematology Middle Aged Proto-Oncogene Proteins c-bcl-2/genetics Proto-Oncogene Proteins c-bcl-2 Proto-Oncogene Proteins c-bcl-6 Lymphomas Female Lymphoma Large B-Cell Diffuse Biomarkers Tumor/genetics Research Article medicine.drug Adult Adolescent Population Etoposide/administration & dosage Biology Research and Analysis Methods Young Adult Internal medicine Gene Expression and Vector Techniques Biomarkers Tumor medicine Immunohistochemistry Techniques Doxorubicin/administration & dosage Cancers and Neoplasms Retrospective cohort study Cell Biology Probe Hybridization Histochemistry and Cytochemistry Techniques Doxorubicin People and Places Immunologic Techniques Prednisone Antineoplastic Combined Chemotherapy Protocols/therapeutic use 030215 immunology
Zdroj:	Pedersen, M Ø, Gang, A O, Brown, P, Pedersen, M, Knudsen, H, Nielsen, S L, Poulsen, T, Wirenfeldt Klausen, T, Høgdall, E & Nørgaard, P 2017, ' Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP-MYC, BCL2 and BCL6 as prognostic biomarkers ', PloS one, vol. 12, no. 10, e0186983 . https://doi.org/10.1371/journal.pone.0186983 PLoS ONE, Vol 12, Iss 10, p e0186983 (2017) PLoS ONE
ISSN:	1932-6203
Popis:	BACKGROUND: Double expression of MYC and BCL2 proteins (DE) and double-hit MYC+BCL2/BCL6 translocations (DH) were established as important biomarkers in patients with diffuse large B-cell lymphoma (DLBCL) by the 2016 revision of the World Health Organization classification of lymphoid neoplasms. Whether this applies to the subgroup of young patients with high risk DLBCL is not known. We previously found that in a uniform retrospective population-based cohort of patients aged 18-60 years with high-risk DLBCL, the addition of etoposide to R-CHOP chemotherapy (R-CHOEP) resulted in improved survival mainly in patients with germinal center B-cell like (GCB) immunophenotype. The aim of this study was to investigate the prognostic and predictive value of DE and DH in this patient cohort.METHODS: Data on all young Danish patients diagnosed with de novo high-risk DLBCL 2004-2008 and treated with R-CHOP or R-CHOEP were obtained from the Danish Lymphoma database (n = 159). Tumor samples were available from 103 patients. MYC and BCL2 proteins were analyzed with quantitative immunohistochemistry (IHC) using different cut off values. MYC-, BCL2- and BCL6-translocations were examined with fluorescent in situ hybridization (FISH).RESULTS: DE with MYC>75% and BCL2>85% was an independent negative prognostic marker of progression free survival (PFS) in patients treated with R-CHOP but not R-CHOEP (pCONCLUSION: In young patients with high-risk DLBCL, treatment with R-CHOEP may overcome the negative prognostic impact of DE observed in patients treated with R-CHOP.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07bb87c57fab7f13f8ff8130c16de6ad https://doi.org/10.1371/journal.pone.0186983 Zobrazit plný text záznamu